Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CNDR-51997
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : National Institute on Aging
Deal Size : $6.9 million
Deal Type : Funding
NIH Awards $6.9 Million to Advance Potential Alzheimer’s Disease Treatment
Details : The proceeds will be used to prepare a potential disease-modifying Alzheimer’s treatment, CNDR-51997, which prevented tau from becoming detached from microtubules, for future clinical trials.
Product Name : CNDR-51997
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 21, 2024
Lead Product(s) : CNDR-51997
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : National Institute on Aging
Deal Size : $6.9 million
Deal Type : Funding
Lead Product(s) : Thrixopelma Pruriens Venom Peptide
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : AmbioPharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Researchers have utilized a venom peptide originally isolated from the Peruvian green velvet tarantula (Thrixopelma pruriens) that blocks Nav1.7 voltage-gated ion channels, an ion channel important in pain signaling.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : Thrixopelma Pruriens Venom Peptide
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : AmbioPharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
‘AeroNabs’ Promise Powerful, Inhalable Protection Against COVID-19
Details : The UCSF team used protein engineering to make a synthetic nanobody that prevents the spike protein on the surface of SARS-CoV-2, the virus that causes COVID-19, from binding to healthy cells and infecting them.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 08, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RLVT-9-01
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Releviate Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Releviate gets an exclusive license for two patents, RLVT-9-01 (anti-MMP-9 antibody) and RLVT-14-02 (anti-MMP-14 antibody) pending human monoclonal antibodies developed by researchers at the University of California, Riverside and Duke University.
Product Name : RLVT-9-01
Product Type : Antibody
Upfront Cash : Undisclosed
October 28, 2020
Lead Product(s) : RLVT-9-01
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Releviate Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : National Institutes of Health
Deal Size : $14.0 million
Deal Type : Funding
UCLA Receives Nearly $14 million from NIH to Investigate Gene Therapy to Combat HIV
Details : The five-year grant, part of an NIH effort to develop gene-engineering technologies to cure HIV/AIDS, will fund a collaboration among UCLA; CSL-Behring, to investigate and further develop an immunotherapy known as CAR T.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 15, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : National Institutes of Health
Deal Size : $14.0 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Cytovia Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the terms and conditions of the agreement, Cytovia will have an exclusive option to license certain patentable inventions developed as part of the research program.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 01, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Cytovia Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Degarelix Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UCLA Researchers to Study Prostate Cancer Drug for Covid-19
Details : The new trial will evaluate the impact of temporarily suppressing male hormones on decreasing the Covid-19 severity to help patients discharge from hospital faster, reduce the need for incubation, and improve mortality.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
May 18, 2020
Lead Product(s) : Degarelix Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
University of California to Assess Whether Hypertension Drug May Reduce COVID-19 Severity
Details : University of California San Diego School of Medicine launch a clinical trial to asses ACE inhibitor drug used to treat heart conditions can lower complexities in Covid-19 infection.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 30, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramipril
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UC San Diego to Assess Hypertension Drug Ramipril for Covid-19
Details : Ramipril will be assessed for its potential to decrease the severity of Covid-19, lower intensive care unit admission rates, mechanical ventilators use, and all-cause mortality.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2020
Lead Product(s) : Ramipril
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable